SuperworthKorsana Biosciences EPS KRSA
Diluted earnings per share by quarter and over the last twelve months, from 2018.
- Last 12 months, to Jun 30, 2026
- −$11.76
- Latest quarter, Q2 FY26
- −$2.87
- Fiscal year 2025
- −$8.26
Korsana Biosciences' earnings per share was −$11.76 over the twelve months to Jun 30, 2026.
In its latest quarter, Q2 FY26, it was −$2.87.
Earnings per share over time
Fiscal year by fiscal year
| Fiscal year | EPS | Change |
|---|---|---|
| FY2025 | −$8.26 | n/a |
| FY2024 | −$8.61 | n/a |
| FY2023 | −$21.00 | n/a |
| FY2022 | −$142.17 | n/a |
| FY2021 | −$189.00 | n/a |
| FY2020 | −$362.60 | n/a |
| FY2019 | −$630.00 | n/a |
| FY2018 | −$589.40 | n/a |
Each fiscal year is the twelve months to its fourth quarter.
Quarter by quarter
| Quarter | Ended | EPS | On a year earlier | Last 12 months |
|---|---|---|---|---|
| Q2 FY26 | −$2.87 | n/a | −$11.76 | |
| Q1 FY26 | −$5.32 | n/a | −$9.66 | |
| Q4 FY25 | −$1.47 | −200% | −$8.26 | |
| Q3 FY25 | −$2.10 | n/a | −$5.32 | |
| Q2 FY25 | −$0.77 | n/a | −$5.25 | |
| Q1 FY25 | −$3.92 | n/a | −$8.19 | |
| Q4 FY24 | $1.47 | n/a | −$8.61 | |
| Q3 FY24 | −$2.03 | −111% | −$14.91 | |
| Q2 FY24 | −$3.71 | n/a | $6.16 | |
| Q1 FY24 | −$4.34 | n/a | −$2.94 | |
| Q4 FY23 | −$4.83 | n/a | −$21.00 | |
| Q3 FY23 | $19.04 | n/a | −$39.41 |
Against its peers
Companies in Drug Manufacturers - General nearest Korsana Biosciences' size, closest first, today.
| Company | EPS, 12 months | Growth |
|---|---|---|
| KRSAKorsana Biosciences | −$11.76 | |
| ATNMActinium Pharmaceuticals | $0.36 | |
| SPROSpero Therapeutics | $0.11 | |
| LFVNLifevantage | $0.40 | −46% a year |
| Peer median | $0.36 |
What the EPS figure tells you
Net income divided by diluted shares. The denominator of PE.
One-off charges and gains swing it. The TTM view smooths a single odd quarter.
More on Korsana Biosciences
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.